This clinical trial is focused on studying the long-term safety and effectiveness of a medication called Povorcitinib for individuals with a skin condition known as Hidradenitis Suppurativa. Hidradenitis Suppurativa is a chronic skin disease that causes small, painful lumps to form under the skin, often in areas where skin rubs together. The study aims to understand how safe Povorcitinib is when used over an extended period.

Participants in the study will take Povorcitinib in the form of a tablet, which is taken orally. The study will last for up to 54 weeks, during which participants will be monitored for any side effects or changes in their condition. Some participants may receive a placebo, which is a tablet that looks like the medication but does not contain the active substance. The study will help determine if Povorcitinib is a safe and effective treatment option for managing the symptoms of Hidradenitis Suppurativa.

Throughout the study, researchers will collect information on any adverse events, which are any unwanted effects that occur while taking the medication. They will also assess how well the medication works in reducing the symptoms of Hidradenitis Suppurativa, such as the number of lumps and tunnels under the skin. This information will contribute to understanding the potential benefits and risks of using Povorcitinib for this condition.